Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
1. NVAX reported Q4 2024 sales of $88.31 million, beating estimates. 2. Earnings loss improved, but still significant at 51 cents per share. 3. Corporate strategy shifts from COVID-19 vaccines to technology platform expansion. 4. Projected revenue of $300-$350 million from licenses and royalties in 2025. 5. Analysts project a price target of $19.0 per share, indicating 141.41% upside.